Benjamin McGraw
Director Ejecutivo en TheraVida, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Luis Peña | M | 61 |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 4 años |
David Eveleth | M | - |
Trefoil Therapeutics, Inc.
Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA. | - |
Eugene Bauer | M | 81 |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 4 años |
Timothy Stonesifer | M | 56 | 2 años | |
Hans Hofland | M | - |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 4 años |
Ben McGraw | M | - |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.
Trefoil Therapeutics, Inc.
Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA. | 2 años |
David Endicott | M | 58 | 2 años | |
Paulette Taylor | F | - |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 28 años |
Leon Sergio Duplan Fraustro | M | 57 | 2 años | |
Tad Heitmann | M | - | 6 años | |
Fred Middleton | M | 74 |
TheraVida, Inc.
TheraVida, Inc. Pharmaceuticals: MajorHealth Technology TheraVida, Inc. develops and commercializes therapeutic products that improve the lives of patients. The firm's products help to treatment of overactive bladder and urge urinary incontinence. It develops a portfolio of combination pharmaceutical products in the fields of urology and central nervous system disorders. The company was founded by Mehdi Paborji in 2005 and is headquartered in Chapel Hill, NC.
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 37 años |
Robert McNeil | M | 81 |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 45 años |
Gregory Jones | M | - | 4 años | |
Leon J. Atencia | M | - | 3 años | |
Carolyn McAuliffe | F | - | 3 años | |
Jeegar Patel | M | - |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 2 años |
Stella M. Robertson | M | - |
Trefoil Therapeutics, Inc.
Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA. | - |
Ian Bell | M | 54 | 2 años | |
Felice Verduyn-van Weegen | F | - |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 3 años |
Allison Gaw | F | - |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 1 años |
George Lasezkay | M | 72 |
TheraVida, Inc.
TheraVida, Inc. Pharmaceuticals: MajorHealth Technology TheraVida, Inc. develops and commercializes therapeutic products that improve the lives of patients. The firm's products help to treatment of overactive bladder and urge urinary incontinence. It develops a portfolio of combination pharmaceutical products in the fields of urology and central nervous system disorders. The company was founded by Mehdi Paborji in 2005 and is headquartered in Chapel Hill, NC. | 10 años |
Michelle Senchyna | M | - | 4 años | |
Royce Bedward | M | 58 | 2 años | |
Janice Drew | F | - |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 4 años |
Nasser Kazeminy | M | - |
TheraVida, Inc.
TheraVida, Inc. Pharmaceuticals: MajorHealth Technology TheraVida, Inc. develops and commercializes therapeutic products that improve the lives of patients. The firm's products help to treatment of overactive bladder and urge urinary incontinence. It develops a portfolio of combination pharmaceutical products in the fields of urology and central nervous system disorders. The company was founded by Mehdi Paborji in 2005 and is headquartered in Chapel Hill, NC. | - |
Pierre Beauparlant | M | - |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 7 años |
Gilles Nobécourt | M | 67 |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | - |
Gary Jay Sternberg | M | - | 2 años | |
Robert Hopfner | M | 51 |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | - |
Michael Dixon | M | - |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 11 años |
David Cohen | M | 59 |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | 4 años |
Peter C. M. McWilliams | M | - |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 24 años |
Timothy C. Mills | M | 68 |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 24 años |
Christy Shaffer | M | 66 |
Trefoil Therapeutics, Inc.
Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA. | - |
Timothy J. Wollaeger | M | 80 |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | 30 años |
Jonathan Balch | M | - | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Richard Rubino | M | 66 | 9 años | |
Vicente J. Anido | M | 71 |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | 20 años |
Edward Danse | M | - |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | 4 años |
Geoff Duyk | M | 64 | 12 años | |
Thomas A. Mitro | M | 66 |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | 20 años |
David Gryska | M | 68 | 8 años | |
Casey C. Kopczynski | M | 62 | 17 años | |
Walter M. Lovenberg | M | 89 |
Marion Merrell Dow, Inc.
| 7 años |
Richard Croarkin | M | 69 | 7 años | |
Peter John McDonnell | M | 66 | 2 años | |
John W. LaRocca | M | 59 | 4 años | |
Julie McHugh | F | 59 | 7 años | |
Gary Menichini | M | - | - | |
Rajkumar Kannan | M | 61 | 1 años | |
Kenneth R. Lynn | M | 70 |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.
Marion Laboratories
| 9 años |
Christopher Staten | M | - | 6 años | |
Michael McCleerey | M | - | 8 años | |
Michael du Toit | M | 71 | 7 años | |
Gerald D. Cagle | M | 79 | 9 años | |
Murray Goldberg | M | 79 | 7 años | |
Joseph A. Markey | M | - |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | - |
Peter Hutt | M | 89 |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | 10 años |
Dennis J. Henner | M | 72 | 4 años | |
Shaun Gentry | M | - | - | |
Erin Horn | M | - | - | |
John Maltman | M | - | 1 años | |
Nils Hauptmann | M | - | - | |
Randall Brown | M | - | - | |
Jeffrey White | M | - | 4 años | |
Robert Finan | M | - | - | |
Ami Bavishi | M | - | - | |
Carmen Wasserman | M | - | - | |
Eric Carlson | M | - | 2 años | |
Welyn Bui | M | - | - | |
Kathleen McGinley | F | 74 | 7 años | |
Charlene E. Davis | F | - | - | |
Brian Levy | M | 72 | 3 años | |
Amine Sinmazisik | F | - | - | |
Nina Ohara | M | - | 2 años | |
Isabel Moredo | F | - | - | |
Brian Sakurada | M | - | - | |
Tori Arens | F | - | 4 años | |
Raymond S. Wysmierski | M | - | - | |
I. Paul Bae | M | 59 | - | |
Paul Clark | M | 76 |
Marion Laboratories
| 1 años |
John J. Reddington | M | - |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 3 años |
Khursheed Anwer | M | 64 |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 2 años |
Jason G. Fewell | M | - |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 4 años |
John H. Vernachio | M | - |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 1 años |
Michael Rowe | M | 62 | 2 años | |
Luis G. Vargas | M | - | 2 años | |
Lee B. Bussey | M | - |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 12 años |
Deanne F. Melloy | F | - | - | |
Sanjay Chanda | M | 59 |
Auration Biotech, Inc.
Auration Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Auration Biotech, Inc. develops novel therapeutics for the treatment of diseases of the ear, nose, and throat. The private company is based in Dover, DE. The company was founded by Sanjay Chanda. Benjamin F. McGraw has been the CEO of the company since 2014. | - |
Richard A. Halprin | M | - | - | |
Richard Lewis | M | - | 7 años | |
Derek Yoon | M | 49 |
Trefoil Therapeutics, Inc.
Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA. | 2 años |
Keith D. Hall | M | 62 |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 6 años |
David Hollander | M | 50 | 3 años | |
Judith Robertson | F | 64 | 2 años | |
Kristine Erickson | M | - | - | |
Huan Sheng | M | - | - | |
Gregory M. McKee | M | 60 |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 3 años |
Peter F. Lang | M | 52 | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 100 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Benjamin McGraw
- Red Personal